Related Experiment Videos
Safety and efficacy of human IgE pentapeptide
Annals of Allergy
|February 1, 1984
Abstract:
The safety, dosage and efficacy of human IgE pentapeptide (HEPP) was evaluated in 12 patients with IgE-mediated atopic disease. Statistically significant differences were observed in allergy symptom scores, allergy medication usage and skin test results between the HEPP treatment and placebo control groups. HEPP appears to be a safe, new therapeutic modality for the treatment of allergic disease.